Who We Are

Reneo is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases with significant unmet medical needs.

Our Work

Reneo is initially developing REN001 in three rare genetic diseases that typically present with myopathy and have a high unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease).

We completed a Phase 1b clinical trial in patients with PMM and are currently enrolling patients in a global Phase 2b clinical trial. We are currently conducting two Phase 1b clinical trials of REN001 in patients with LC-FAOD and McArdle disease, respectively. Both Phase 1b trials are currently enrolling.

Leadership Team

Meet the Reneo Executive Team!

Gregory J. Flesher

President & Chief Executive Officer

Vinny Jindal

Chief Financial Officer

Alejandro Dorenbaum, M.D.

Chief Medical Officer

Ashley F. Hall, J.D.

Chief Development Officer

Wendy Johnson

Chief Business Officer

Lynn Purkins, Ph.D.

Senior Vice President of Clinical Operations

Michael Cruse

Senior Vice President of Corporate Operations

Board of Directors

Partner
With Reneo

Reneo works with investor partners to enable continued progress in our clinical development programs.

MIKE GREY

Executive Chairman

LON CARDON, PH.D.

Eric Dube, Ph.D.

GREGORY J. FLESHER

President & Chief Executive Officer

Kenneth Harrison

Ed Mathers

Bali Muralidhar

Niall O’Donnell

Stacey D. Seltzer